CPDC Announces Appointment of Justyna Kelly as Permanent CEO

June 23, 2020 CPDC

Hamilton, Ontario June 23, 2020

The Centre for Probe Development and Commercialization (CPDC) announced that its Board of Directors has appointed Justyna Kelly as Chief Executive Officer (CEO). The CEO appointment has taken effect on June 18, 2020.

Justyna Kelly was appointed the role of interim CEO in December 2019. Mark Lundie, outgoing Chair of the Board of Directors said, “Justyna has led the Centre very well over the past 6 months and navigated a particularly challenging time through the global economy. I am confident that Justyna will provide the leadership and expertise needed to guide the Centre through the next phase of growth. The Board and I are delighted to appoint Justyna as CPDC’s CEO.”

Ms. Kelly has been with the CPDC for 10 years, and has been involved in a wide breadth of CPDC’s operations, including leading CPDC’s microbiology and sterility assurance program as well as radiopharmaceutical development and manufacturing initiatives, and leading key internal programs and launching a number of therapeutic products.

“I am very grateful for this opportunity; CPDC is truly a unique and talented organization. I look forward to continuing working with this amazing team to deliver to our stakeholders, partners and patients” noted Ms. Kelly. “I look forward to driving CPDC’s mission to transform patients’ lives by advancing high quality drugs for the diagnosis and treatment of diseases.”

The Company also announced that Dr. John Thornback, Vice President and COO at Diagnostics Development Hub, Exploit Technologies Pte Ltd. and Chair of Sestria Ltd., has been appointed as the new Board Chair effective June 18, 2020. Dr. Thornback has served as a CPDC Board Member since its formation. He has over 40 years experience in the radiopharmaceutical and in vitro diagnostics industry having been CEO of a number of biotech companies in Canada, UK, and Singapore, spanning both start-ups and privatisations of government institutes. He is currently the Chief Operating Officer of the Diagnostics Development Hub, a Singapore government National Centre of Excellence tasked with developing a medical diagnostics industry through the productisation of concepts and ideas developed in Singapore.

About CPDC
The Centre for Probe Development and Commercialization (CPDC) is a private, not-for-profit company dedicated to improving patient’s lives by advancing drugs for the diagnosis and treatment of diseases. Created in 2008, with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University and the Ontario Institute for Cancer Research (OICR), CPDC has become a global leader in the discovery, development and commercialization of next-generation radiopharmaceuticals. With an established pipeline of products and a robust and reliable manufacturing unit, CPDC supplies innovative diagnostic and therapeutic radiopharmaceuticals that are used daily in

More news from CPDC

ARTMS Inc. announces Health Canada Submission for Ga-68 Production and Tri-party Collaboration to Advance Ga-68 Imaging Products

Burnaby, Canada, October 14, 2021 – ARTMS Inc. (ARTMS), the global leader in developing and commercializing novel products enabling cyclotron production of the world’s most needed medical radioisotopes, is pleased to announce the submission of a Type 1 Master File with the Health Products & Food Branch, Health Canada (HC) for the production of gallium-68

CPDC Announces Four New Appointments To Board of Directors

HAMILTON, ON, July 13, 2021 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, announced today that it has appointed four new Members to join its Board of Directors effective June 17, 2021.  The new Members are as follows: Dr. Bettina Hamelin, is the current President and

The CARI program and overcoming commercialization challenges in the Canadian isotope sector

CARI is a collaboration between The Centre for Probe Development and Commercialization (CPDC) and adMare BioInnovations (adMare) working to bring respective resources together to advance an area of tremendous therapeutic and commercial potential in which Canada can gain considerable global competitive advantage in radiopharmaceuticals. Join us for this event where we will learn how the

For more information contact us at: